RxDoctor Payments DataLook up a doctor →

Robert Capodilupo, MD

Cardiovascular Disease · Manchester, NHNPI 1619953536

Payments from drug & device makers

$528,782in general payments, 2019–2025

Across 406 payments — averaging $1302.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$293K
  • Boston Scientific$179K
  • Lantheus Medical Imaging, Inc.$33K
  • Philips North America LLC$18K
  • Medtronic$2K
  • Edwards Lifesciences$2K
  • plus $2K from 11 others
$2,100in research payments, 2019–2025

Across 2 payments — averaging $1050.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$2K

What the payments were for

  • Consulting fees$10,21612%
  • Speaking & faculty fees$57,85068%
  • Travel & lodging$6,8248%
  • Food & beverage$9,95012%
  • Education$1510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$528,782 in reported general payments places this provider in the 95th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$157,840
Medicare patients
2,149
Services billed
4,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis16$616,326
EliquisApixaban305$352,320
EntrestoSacubitril/Valsartan72$83,961
XareltoRivaroxaban66$58,923
JardianceEmpagliflozin37$34,460
Metoprolol Succinate431$6,044
Torsemide95$4,743
Flecainide Acetate30$3,273
Diltiazem 24hr Er (Cd)Diltiazem Hcl54$2,611
Potassium Chloride105$2,252
Atorvastatin Calcium209$1,641
Amiodarone Hcl68$1,227
Mexiletine Hcl11$1,148
Rosuvastatin Calcium80$1,100
Furosemide161$1,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$152$968,646321 claims
Boehringer IngelheimJardiance$364$34,46037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 cardiovascular disease providers in New Hampshire.

Other cardiovascular disease in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →